SCHEMBL3552749

SCHEMBL3552749

CN(C)CCNC1=CC(=O)c2sc(C(=O)Nc3ccc(Cl)cc3)nc2C1=O

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 2/20 0.57
CDC25B P30305 2/20 0.57
CDC25C P30307 2/20 0.57
CDK4 P11802 7/20 0.48
MALT1 Q9UDY8 1/20 0.40
ALDH1A1 P00352 1/20 0.39
LMNA P02545 2/20 0.39
POLB P06746 1/20 0.39
MEN1 O00255 1/20 0.38
THRB P10828 1/20 0.38
CCND1 P24385 1/20 0.38
BLM P54132 1/20 0.38
KMT2A Q03164 1/20 0.38
KMT5A Q9NQR1 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MAPT P10636 2/20 0.38
HRH3 Q9Y5N1 1/20 0.36
TSHR P16473 1/20 0.36
NR3C1 P04150 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3541211 0.90 CDC25A (0.57) CDC25ACDC25BCDC25CCDK4MALT1
SCHEMBL3547884 0.89 CDC25A (0.55) CDC25ACDC25BCDC25CCDK4MALT1
SCHEMBL3549687 0.83 CDC25A (0.51) CDC25ACDC25BCDC25CALDH1A1POLB
SCHEMBL3553927 0.82 CDC25A (0.50) CDC25ACDC25BCDC25CCDK4
SCHEMBL3548433 0.81 CDC25A (0.64) CDC25ACDC25BCDC25CCDK4MALT1
SCHEMBL1919178 0.81 CDC25A (0.64) CDC25ACDC25BCDC25CCDK4MALT1
SCHEMBL2399999 0.81 CDK4 (0.47) CDC25ACDC25BCDC25CCDK4POLB
SCHEMBL2400025 0.79 CDK4 (0.48) CDC25ACDC25BCDC25CCDK4ALDH1A1
SCHEMBL3547085 0.79 CDC25A (0.60) CDC25ACDC25BCDC25CCDK4MALT1
SCHEMBL3550893 0.79 CDC25A (0.60) CDC25ACDC25BCDC25CCDK4MALT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317658-A1 4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses IPSEN PHARMA S.A.S. (FR) 2010-12-16 US claimed
US-7795284-B2 4,7-dioxobenzothiazole-2-carboxamide derivatives, their preparation and their therapeutic uses IPSEN PHARMA S.A.S. (FR) 2010-09-14 US claimed
EP-1814879-B1 DERIVATIVES OF 4,7-DIOXOBENZOTHIAZOLE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND THERAPEUTIC USES OF SAME SOD CONSEILS RECH APPLIC (FR) 2008-09-24 EP claimed
US-20070244186-A1 4, 7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation and Their Therapeutic Uses IPSEN PHARMA S.A.S. (FR) 2007-10-18 US claimed
US-20100317658-A1 4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses IPSEN PHARMA S.A.S. (FR) 2010-12-16 US disclosed
US-7795284-B2 4,7-dioxobenzothiazole-2-carboxamide derivatives, their preparation and their therapeutic uses IPSEN PHARMA S.A.S. (FR) 2010-09-14 US disclosed
EP-1814879-B1 DERIVATIVES OF 4,7-DIOXOBENZOTHIAZOLE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND THERAPEUTIC USES OF SAME SOD CONSEILS RECH APPLIC (FR) 2008-09-24 EP disclosed
US-20070244186-A1 4, 7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation and Their Therapeutic Uses IPSEN PHARMA S.A.S. (FR) 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244186-A1 4, 7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation and Their Therapeutic Uses CDC25C, CDC25A, CDC25B CDC25A 2/4885CDC25B 3/4885CDC25C 1/4885
US-20100317658-A1 4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses CDC25C, CDC25A, CDC25B CDC25A 2/4885CDC25B 3/4885CDC25C 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.